Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Purpose
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: - What side effects REGN20934 might cause - How much REGN20934 is in the blood at different times - If the body makes antibodies to REGN20934
Condition
- Overweight or Obesity
Eligibility
- Eligible Ages
- Between 18 Years and 65 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Has a Body Mass Index (BMI) 25 to 35 kg/m^2 2. Females must be of non-childbearing potential
Exclusion Criteria
- A self-reported change of body weight >5 kg within approximately 90 days of visit 2 2. History of type 1 or type 2 diabetes 3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol Note: Other protocol defined inclusion/exclusion criteria apply
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- Sponsor unblinded
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental REGN20934 |
|
|
|
Placebo Comparator Placebo |
|
Recruiting Locations
California Clinical Trials Medical Group
Glendale, California 91206
Glendale, California 91206
More Details
- Status
- Recruiting
- Sponsor
- Regeneron Pharmaceuticals